WA HB2196

Health carriers must cover initial three monthly courses of intravenous immunoglobulin (IVIG) therapy for PANDAS and PANS treatment, with additional courses as medically necessary, for plans issued or renewed on or after January 1, 2027

Coverage requires that two less intensive treatments were tried and found ineffective, not tolerated, or did not result in sustained improvement, and the treating provider recommends the treatment

Carriers may require clinical reevaluation at three-month intervals but cannot deny coverage based on prior treatment for the same condition, the patient's age, or a different diagnostic name such as autoimmune encephalopathy

Coverage limitations must be consistent with treatment guidelines developed by research consortiums, and carriers cannot require trials of therapies that only treat neuropsychiatric symptoms before covering IVIG

Out-of-state treatment must be covered if the service is not available within Washington state; exempts public employee health plans under chapter 41.05 RCW